Coronavirus / COVID

Rebound in COVID-19 symptoms, retesting positive for SARS-CoV-2, and recurring infectivity after Paxlovid treatment mars "test and treat."

Moderna’s bivalent COVID-19 vaccine booster, mRNA-1273.214, generated nearly twice the protective antibodies against Omicron.

The vote was 21-0 in favor of an emergency use authorization (EUA), with one voter abstaining.

Impairment of cognitive function is a growing, concerning effect of "long COVID."

Adults living with HIV were more likely to have a breakthrough COVID-19 infection after vaccination, suggesting a need for additional vaccine doses in this population.

The advisory group is meeting on Tuesday to discuss the vaccine’s presenting data and a potential authorization.

New vaccine for COVID-19 employing receptor-binding domain-dimer-based platform achieves 87.6% efficacy against severe to critical illness.

The study authors determined that COVID-19 patients with HIV were 38% more likely to die than those without HIV.

COVID-19 mortality is most frequent in men 60-77 years old with acute lung injury.

The White House coronavirus response coordinator said vaccines for children under 5 could potentially begin on June 21.

New research in Israel offers hope that multisystem inflammatory syndrome in children—a serious complication of COVID-19—declined during the Omicron surge of the pandemic.

In 2020, COVID-19 mortality rates were 5 times higher among adults in low socioeconomic positions.

Synairgen's inhalable Interferon-beta treatment, SNG001, may be a treatment option for hospitalized and immunocompromised COVID-19 patients.

The organization is behind community-based funding and educational programs to propel a healthier society at a grassroots level.

Medical professionals discuss how they affect immunity as well as the necessity of these additional vaccinations.

This crisis has united multidisciplinary groups and laid the foundation to better equip the health care workforce for future pandemics.

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.

Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.

With few exceptions, COVID-19 therapies have not been studied comparatively, so choosing therapies to preferentially recommend is difficult and is done, instead, by strength of evidence and quality of data.

The need for safe and effective treatment against the various strains of COVID-19 increase, and investigators continue to assess various pharmacologic options.

Available literature on thrombosis occurrence in COVID-19 patients focuses on hospitalized cases. A new study sheds light on the incidence of thromboembolism in less severe cases of disease,

The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.

A new study from the CDC underscores the importance of staying up to date on COVID-19 vaccines and boosters, showing a rapid drop in vaccine effectiveness among children during the Omicron wave that increased with booster doses.

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization (EUA).

At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.